# Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia

> **NCT00281931** · PHASE2 · TERMINATED · sponsor: **German CLL Study Group** · enrollment: 21 (estimated)

## Conditions studied

- Prolymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** cyclophosphamide
- **DRUG:** fludarabine phosphate

## Key facts

- **NCT ID:** NCT00281931
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-09
- **Primary completion:** 2006-04
- **Final completion:** 2006-10
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2016-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281931, "Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00281931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*